SUPPORT2

This dataset comprises 9105 individual critically ill patients across 5 United States medical centers, accessioned throughout 1989-1991 and 1992-1994. Each row concerns hospitalized patient records who met the inclusion and exclusion criteria for nine disease categories: acute respiratory failure, chronic obstructive pulmonary disease, congestive heart failure, liver disease, coma, colon cancer, lung cancer, multiple organ system failure with malignancy, and multiple organ system failure with sepsis. The goal is to determine these patients' 2- and 6-month survival rates based on several physiologic, demographics, and disease severity information. It is an important problem because it addresses the growing national concern over patients' loss of control near the end of life. It enables earlier decisions and planning to reduce the frequency of a mechanical, painful, and prolonged dying process.

Characteristics
Tabular, Multivariate
Subject Area
Health and Medicine
Associated Tasks
Classification, Regression, Other

Attribute Type
--
# Instances
9.11k
# Attributes
42

Info

Data sources are medical records, personal interviews, and the National Death Index (NDI). For each patient administrative records data, clinical data and survey data were collected. The objective of the SUPPORT project was to improve decision-making in order to address the growing national concern over the loss of control that patients have near the end of life and to reduce the frequency of a mechanical, painful, and prolonged process of dying. SUPPORT comprised a two-year prospective observational study (Phase I) followed by a two-year controlled clinical trial (Phase II). Phase I of SUPPORT collected data from patients accessioned during 1989-1991 to characterize the care, treatment preferences, and patterns of decision-making among critically ill patients. It also served as a preliminary step for devising an intervention strategy for improving critically-ill patients' care and for the construction of statistical models for predicting patient prognosis and functional status. An intervention was implemented in Phase II of SUPPORT, which accessioned patients during 1992-1994. The Phase II intervention provided physicians with accurate predictive information on future functional ability, survival probability to six months, and patients' preferences for end-of-life care. Additionally, a skilled nurse was provided as part of the intervention to elicit patient preferences, provide prognoses, enhance understanding, enable palliative care, and facilitate advance planning. The intervention was expected to increase communication, resulting in earlier decisions to have orders against resuscitation, decrease time that patients spent in undesirable states (e.g., in the Intensive Care Unit, on a ventilator, and in a coma), increase physician understanding of patients' preferences for care, decrease patient pain, and decrease hospital resource use. Data collection in both phases of SUPPORT consisted of questionnaires administered to patients, their surrogates, and physicians, plus chart reviews for abstracting clinical, treatment, and decision information. Phase II also collected information regarding the implementation of the intervention, such as patient-specific logs maintained by nurses assigned to patients as part of the intervention. SUPPORT patients were followed for six months after inclusion in the study. Those who did not die within six months or were lost to follow-up were matched against the National Death Index to identify deaths through 1997. Patients who did not die within one year or were lost to follow-up were matched against the National Death Index to identify deaths through 1997. All patients in five United States medical centers who met inclusion and exclusion criteria for nine disease categories: acute respiratory failure, chronic obstructive pulmonary disease, congestive heart failure, liver disease, coma, colon cancer, lung cancer, multiple organ system failure with malignancy, and multiple organ system failure with sepsis. SUPPORT is a combination of patients from 2 studies, each of which lasted 2 years. The first phase concerns 4,301 patients, whereas the second phase concerns 4,804 patients. Time wise, these studies were accessioned in 1989 (June 12) through 1991 (June 11) for phase I and in 1992 (January 7) through 1994 (January 24).


Introductory Paper

A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT)

By The SUPPORT Principal Investigators. 1995

Published in In the Journal of the American Medical Association, 274(20):1591–1598

Provided by
University of California, Irvine


Creators
  • Frank Harrel

DOI

10.3886/ICPSR02957.v2

Login to Download

New to AIM-AHEAD Connect?
Create an account!

Features

Attribute Name Role Type Demographic Description Units Missing Values
id ID Integer no
age Feature Continuous Age Age of the patients in years years no
death Target Continuous Death at any time up to National Death Index (NDI) data on 31 of December of 1994. Some patients are discharged before the end of the study and are not followed up. The authors looked up the information about death. no
sex Feature Categorical Sex Gender of the patient. Listed values are {male, female}. no
hospdead Target Binary Death in hospital no
slos Other Continuous Days from Study Entry to Discharge no
d.time Other Continuous Days of follow-up no
dzgroup Feature Categorical The patient's disease sub category amogst ARF/MOSF w/Sepsis, CHF, COPD, Cirrhosis, Colon Cancer, Coma, Lung Cancer, MOSF w/Malig. no
dzclass Feature Categorical The patient's disease category amongst "ARF/MOSF", "COPD/CHF/Cirrhosis", "Cancer", "Coma". no
num.co Feature Continuous The number of simultaneous diseases (or comorbidities) exhibited by the patient. Values are ordinal with higher values indicating worse condition and chances of survival. no
edu Feature Categorical Education Level Years of education years yes
income Feature Categorical Income Income of the patient. Listed values are {"$11-$25k", "$25-$50k", ">$50k", "under $11k"}. yes
scoma Feature Continuous SUPPORT day 3 Coma Score based on Glasgow scale (predicted by a model). yes
charges Feature Continuous Hospital charges yes
totcst Feature Continuous Total ratio of costs to charges (RCC) cost yes
totmcst Feature Continuous Total micro cost yes
avtisst Feature Continuous Average TISS score, days 3-25, where Therapeutic Intervention Scoring System (TISS) is a method for calculating costs in the intensive care unit (ICU) and intermediate care unit (IMCU). yes
race Feature Categorical Race Race of the patient. Listed values are {asian, black, hispanic, missing, other, white}. yes
sps Feature Continuous SUPPORT physiology score on day 3 (predicted by a model). yes
aps Feature Continuous APACHE III day 3 physiology score (no coma, imp bun,uout for ph1) yes
surv2m Feature Continuous SUPPORT model 2-month survival estimate at day 3 (predicted by a model) yes
surv6m Feature Continuous SUPPORT model 6-month survival estimate at day 3 (predicted by a model) yes
hday Feature Integer Day in hospital at which patient entered study. no
diabetes Feature Continuous Whether the patient exhibits diabetes (Com 27-28, Dx 73) as a comorbidity (Y) or not (N). no
dementia Feature Continuous Whether the patient exhibits dementia (Comorbidity 6) as a comorbidity (Y) or not (N). no
ca Feature Categorical Whether the patient has cancer (yes), whether it has spread out (metastatic), or if it is healthy (no). no
prg2m Feature Continuous Physician’s 2-month survival estimate for patient. yes
prg6m Feature Categorical Physician’s 6-month survival estimate for patient. yes
dnr Feature Categorical Whether the patient has a do not rescuscitate (DNR) order or not. Possible values are dnr after sadm, dnr before sadm, missing, no dnr. yes
dnrday Feature Continuous Day of DNR order (<0 if before study) yes
meanbp Feature Continuous mean arterial blood pressure of the patient, measured at day 3. yes
wblc Feature Continuous counts of white blood cells (in thousands) measured at day 3. yes
hrt Feature Continuous heart rate of the patient measured at day 3. yes
resp Feature Continuous respiration rate of the patient measured at day 3. yes
temp Feature Continuous temperature in Celsius degrees measured at day 3. no
pafi Feature Continuous $PaO_2/FiO_2$ ratio measured at day 3. The ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction). Widely used clinical indicator of hypoxaemia, though its diagnostic utility is controversial. Specific ranges of values can be associated with different levels of mortality. May be worth considering binning these values according to some ranges: https://litfl.com/pao2-fio2-ratio/ yes
alb Feature Continuous serum albumin levels measured at day 3. yes
bili Feature Continuous bilirubin levels measured at day 3. yes
crea Feature Continuous serum creatinine levels measured at day 3. yes
sod Feature Continuous serum sodium concentration measured at day 3. yes
ph Feature Continuous Arterial blood pH. The pH of blood is usually between 7.35 and 7.45. Abnormal results may be due to lung, kidney, metabolic diseases, or medicines. Head or neck injuries or other injuries that affect breathing can also lead to abnormal results. yes
glucose Feature Integer Glucose levels measured at day 3. yes
bun Feature Integer Blood urea nitrogen levels measured at day 3. yes
urine Feature Integer Urine output measured at day 3. yes
adlp Feature Categorical Index of Activities of Daily Living (ADL) of the patient, filled out by the patient. Higher values indicate more chance of survival, measured at day 3. yes
adls Feature Continuous Index of Activities of Daily Living (ADL) of the patient, filled out by a surrogate (e.g. family member), measured at day 3. Higher values indicate more chance of survival. yes
sfdm2 Target Categorical Level of functional disability of the patient in a 1-5 scale, with 5 being the highest severity. The values were obtained via questionairres to the patient and/or surrogates to determine the Sickness Profile Impact (SIP). Values are correlated with ADLS, ADLP columns. Listed values are: {1: "no(Month 2 and SIP pres)", "adl>=4 (>=5 if sur)", "SIP>=30", "Coma or Intub", 5: "<2 mo. follow-up"}. There are 159 patients surviving 2 months for whom there were no patient or surrogate interviews. These patients have missing sfdm2. yes
adlsc Feature Continuous Imputed ADL Calibrated to Surrogate. no